ArticleJournal of the American Heart Association2021
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).Current cardiology reports · 2026Pooled it
- Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review.International journal of molecular sciences · 2025Pooled it
- Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.BMC gastroenterology · 2023Trial
- Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions.Diabetologia · 2026Review
- Cardiovascular disease risk in patients with and without metabolic dysfunction-associated steatotic liver disease: A clinical and subclinical evaluation.American heart journal plus : cardiology research and practice · 2026Review
- The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients · 2026Review
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Association between high-risk metabolic dysfunction-associated steatohepatitis and ischemic heart disease: a nationally representative study.Nutrition journal · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Reviews in cardiovascular medicine · 2026Review
- C-reactive protein-triglyceride glucose index as a predictor of heart failure risk in adults with MASLD: a prospective cohort study.Scientific reports · 2026Article
- Metabolic markers of kidney function and oxidative stress are associated with heart failure with preserved ejection fraction (HFpEF) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review.World journal of cardiology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective.Frontiers in pharmacology · 2026Review
- Association between metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction.Przeglad gastroenterologiczny · 2026Review
- Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH.JHEP reports : innovation in hepatology · 2026Article
- Chronic liver disease is associated with greater risk of hospital readmission in patients with heart failure: a nationwide database study in the US.European heart journal open · 2026Article
- Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit With GLP-1/Glucagon Agonism.JACC. Basic to translational science · 2025Article
- Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease.Communications medicine · 2025Review
- Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.World journal of cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
Background Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are increasing in prevalence. The independent association between NAFLD and downstream risk of HF and HF subtypes (HF with preserved ejection fraction and HF with reduced ejection fraction) is not well established. Methods and Results This was a retrospective, cohort study among Medicare beneficiaries. We selected Medicare beneficiaries without known prior diagnosis of HF. NAFLD was defined using presence of 1 inpatient or 2 outpatient claims using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.